I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site

Diffuse Large B-Cell Lymphoma

What's new

Sign up or login to unlock the full suite of MEDICALLY features

Dec 9 / Roche and Genentech
Primary results of patient-reported outcomes in patients with relapsed/refractory diffuse large B-cell lymphoma treated with glofitamab▼ plus gemcitabine and oxaliplatin (Glofit-GemOx) versus rituximab plus GemOx (R-GemOx) from the Phase III STARGLO study
STARGLO is a Phase III study of glofitamab▼ plus gemcitabine and oxaliplatin (GemOx; Glofit-GemOx) versus rituximab plus GemOx in autologous stem cell transplant-ineligible patients with relapsed/refractory diffuse large B-cell lymphoma. This abstract presents patient-reported outcomes to capture the impact of treatment on health-related quality of life of patients from the STARGLO trial.

Sign up or login to unlock the full suite of MEDICALLY features

Dec 9 / Roche and Genentech
Glofitamab▼ with gemcitabine and oxaliplatin is cost-effective versus rituximab with gemcitabine and oxaliplatin for US patients with relapsed/refractory diffuse large B-cell lymphoma who were not candidates for autologous stem cell transplant
STARGLO is a Phase III study of glofitamab▼ plus gemcitabine and oxaliplatin (GemOx; Glofit-GemOx) versus rituximab plus GemOx in autologous stem cell transplant-ineligible patients with relapsed/refractory diffuse large B-cell lymphoma. A cost-effectiveness analysis of these treatments, from a United States payer perspective, is presented.

Sign up or login to unlock the full suite of MEDICALLY features

Dec 9 / Roche and Genentech
Fixed-duration glofitamab▼ monotherapy continues to demonstrate durable responses in patients with relapsed or refractory large B-cell lymphoma: 3-year follow-up from a pivotal Phase II study
NP30179 is a Phase II study of fixed-duration glofitamab▼ monotherapy in patients with relapsed or refractory large B-cell lymphoma. This abstract presents updated data from the 3-year follow-up of NP30179, including a landmark analysis of the outcomes of patients in complete remission and an exploratory biomarker analysis of the risks and benefits of fixed-duration treatment.
Upcoming congresses
Access to Roche and Genentech’s latest medical information
View related congresses

Ask a question or share feedback